- Home
- CALC vs BTLN Comparison
CALC vs BTLN Comparison
Compare CALC & BTLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CALC | BTLN |
|---|---|---|
| Founded | 2011 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.1M | 20.3M |
| IPO Year | 2020 | 2021 |
Fundamental Metrics
Financial Performance| Metric | CALC | BTLN |
|---|---|---|
| Price | $1.70 | $4.96 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $10.00 | N/A |
| AVG Volume (30 Days) | 79.0K | ★ 184.8K |
| Earning Date | 05-13-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.44 | $0.52 |
| 52 Week High | $7.20 | $6.56 |
Technical Indicators
Market Signals| Indicator | CALC | BTLN |
|---|---|---|
| Relative Strength Index (RSI) | 51.75 | 80.81 |
| Support Level | $0.51 | $0.68 |
| Resistance Level | $2.31 | $5.53 |
| Average True Range (ATR) | 0.13 | 0.67 |
| MACD | -0.08 | 0.40 |
| Stochastic Oscillator | 7.46 | 66.08 |
Price Performance
Historical ComparisonAbout CALC CalciMedica Inc.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. The company operates as one operating segment focused on developing and commercializing therapeutics in the U.S.